A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520286-31-00

Enrollment

Registered

2026-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hot Flush

None listed

Sex/Gender

Male

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Apr 4, 2026